(NewsDirect)
Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tellsProactive the company has made great progress towardscommercialisation in a Phase 1C study of its topical Pan LOXinhibitor, achieving a well-tolerated safety profile and a markedchange in scar composition. Importantly, the study’s results markthe first-ever proof that LOX inhibition reduces skin collagen, havingachieved a 30% reduction in the scar’s collagen content.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.